RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Merck reported its Keytruda PD-1 drug was approved in China for first-line use in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), a potentially blockbuster indication. In a global clinical trial, Keytruda reduced deaths by 50% in lung cancer patients. Previously, Keytruda was approved in China as a second-line treatment for metastatic melanoma, a much smaller market. Opdivo, the Bristol-Myers Squibb PD-1 treatment, was approved last year in China as a second-line treatment for NSCLC.
Source: China Biotoday
